MONO group N=228 | COMBO group N=349 | All patients N=577 | |
---|---|---|---|
Tocilizumab | |||
Number of infusions | 9.1±4.3 | 9.7±4.0 | 9.4±4.1 |
Treatment duration (months) | 8.64±4.30 | 9.07±4.00 | 8.90±4.12 |
Patients with ≥1 modification of tocilizumab treatment, n (%) | 118 (51.8) | 153 (43.8) | 271 (47.0) |
Patients with ≥1 change in dose | 35* (29.7) | 45 (29.4) | 80† (29.5) |
At least one dose decrease | 29 (82.9) | 44 (97.8) | 73 (91.3) |
Patients with ≥1 temporary discontinuation | 29 (24.6) | 50 (32.7) | 79 (29.2) |
Permanent discontinuation | 70 (59.3) | 93 (60.8) | 163 (60.1) |
csDMARDs, n (%) | |||
Patients with ≥1 combined csDMARD at inclusion | 0 (0.0) | 349 (100.0) | 349 (60.5) |
MTX | 268 (76.8) | ||
Other csDMARDs | 72 (20.6) | ||
MTX and other csDMARD | 9 (2.6) | ||
Patients with ≥1 combined csDMARD over the study period | 20 (8.8) | 349 (100.0) | 369 (64.0) |
Patients with ≥1 change in combined | |||
csDMARDs after inclusion | 12 (5.3) | 80 (22.9) | 92 (15.9) |
Patients with ≥1 change in dose | 8 (3.5) | 52 (14.9) | 60 (10.4) |
Patients with ≥1 temporary discontinuation | 1 (0.4) | 13 (3.7) | 14 (2.4) |
Permanent discontinuation | 4 (1.7) | 25 (7.2) | 29 (5.0) |
Oral glucocorticoids, n (%) | |||
Dose of oral glucocorticoids at M12 (mg/daily equivalent prednisone) | |||
Missing data | 98 (43) | 142 (40.6) | 240 (41.5) |
0 | 64 (28.1) | 103 (29.5) | 167 (28.9) |
[0–5] | 36 (15.8) | 48 (13.75) | 84 (14.5) |
[5–7.5] | 8 (3.5) | 23 (6.6) | 31 (5.4) |
[7.5–10] | 13 (5.7) | 20 (5.7) | 33 (5.7) |
>10 | 9 (3.9) | 13 (3.7) | 22 (3.8) |
*One patient had dose decrease and dose increase over the study period.
†Data are presented as n (%) unless stated otherwise.
csDMARD, conventional synthetic disease-modifying antirheumatic drug; COMBO, tocilizumab in combination with csDMARD at inclusion; MONO, tocilizumab as monotherapy at inclusion; MTX, methotrexate.